The Basics
What is Samarium Sm 153 Lexidronam Pentasodium?
Used to treat pain when cancer has spread to the bone.
Brand names for Samarium Sm 153 Lexidronam Pentasodium
Quadramet
How Samarium Sm 153 Lexidronam Pentasodium is classified
Radiopharmaceuticals, Samarium Radioisotopes
Samarium Sm 153 Lexidronam Pentasodium During Pregnancy
Samarium Sm 153 Lexidronam Pentasodium pregnancy category
Category DNote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.
What we know about taking Samarium Sm 153 Lexidronam Pentasodium while pregnant
As with other radiopharmaceutical drugs, QUADRAMET® can cause fetal harm whenadministered to a pregnant woman. Adequate and well controlled studies have not beenconducted in animals or pregnant women. Women of child-bearing age should have a negativepregnancy test before administration of QUADRAMET®. If this drug is used during pregnancy, orif a patient becomes pregnant after taking this drug, the patient should be apprised of thepotential hazard to the fetus. Women of childbearing potential should be advised to avoidbecoming pregnant soon after receiving QUADRAMET®. Men and women patients should beadvised to use an effective method of contraception after the administration of QUADRAMET®.
Taking Samarium Sm 153 Lexidronam Pentasodium While Breastfeeding
What are recommendations for lactation if you're taking Samarium Sm 153 Lexidronam Pentasodium?
Information in this record refers to the use of samarium Sm 153 lexidronam pentasodium as a therapeutic agent. No information is available on the use of samarium Sm 153 lexidronam pentasodium during breastfeeding. Most conditions treated with samarium Sm 153 would not occur in mothers wishing to nurse. However, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. Because of the relatively long half-life of samarium 153, the standard waiting period of 10 half-lives would be close to 3 weeks which might be impractical for resuming breastfeeding. The manufacturer and expert opinion recommend discontinuing breastfeeding if the agent is administered.[1] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]
Maternal / infant drug levels
Information in this record refers to the use of samarium Sm 153 lexidronam pentasodium as a therapeutic agent. No information is available on the use of samarium Sm 153 lexidronam pentasodium during breastfeeding. Most conditions treated with samarium Sm 153 would not occur in mothers wishing to nurse. However, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. Because of the relatively long half-life of samarium 153, the standard waiting period of 10 half-lives would be close to 3 weeks which might be impractical for resuming breastfeeding. The manufacturer and expert opinion recommend discontinuing breastfeeding if the agent is administered.[1] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]
Possible effects of Samarium Sm 153 Lexidronam Pentasodium on milk supply
Relevant published information was not found as of the revision date.
Possible alternatives to Samarium Sm 153 Lexidronam Pentasodium
None listed
List of References
Lactation sources: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/1. Bodei L, Lam M, Chiesa C et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008;35:1934-40. PMID: 18649080
2. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203
Disclaimer: This material is provided for educational purposes only and is not intended for medical advice, diagnosis, or treatment. Consult your healthcare provider with any questions.
